Condensed Consolidated Statements of Changes In Stockholders' Equity (Unaudited) - USD ($)	Total	Common Stock [Member]	Common Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Series A Preferred Stock [Member]	Additional Paid-In Capital [Member] Series B Preferred Stock [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2023	$ 57,299,441	$ 929			$ 5				$ 152,856,874			$ (5,521,246)	$ (90,063,541)	$ 26,420
Balance (in shares) at Dec. 31, 2023		9,280,159			42,236
Balance (in shares) at Dec. 31, 2023												(54,665)
Stock-based compensation	617,445								617,445
Issuance of common stock for exercise of stock options	20,412								20,412
Issuance of common stock for exercise of stock options (in shares)		3,780
Net income (loss)	(5,025,745)												(5,025,745)
Foreign currency translation	(33,807)													(33,807)
Unrealized gain (loss), change in fair value of available-for-sale securities	(56,061)													(56,061)
Balance at Mar. 31, 2024	52,821,685	$ 929			$ 5				153,494,731			$ (5,521,246)	(95,089,286)	(63,448)
Balance (in shares) at Mar. 31, 2024		9,283,939			42,236
Balance (in shares) at Mar. 31, 2024												(54,665)
Balance at Dec. 31, 2023	57,299,441	$ 929			$ 5				152,856,874			$ (5,521,246)	(90,063,541)	26,420
Balance (in shares) at Dec. 31, 2023		9,280,159			42,236
Balance (in shares) at Dec. 31, 2023												(54,665)
Net income (loss)	(22,710,610)
Balance at Sep. 30, 2024	36,902,617	$ 929			$ 5				155,144,947			$ (5,521,246)	(112,774,151)	52,133
Balance (in shares) at Sep. 30, 2024		9,283,939			42,236
Balance (in shares) at Sep. 30, 2024												(54,665)
Balance at Dec. 31, 2023	57,299,441	$ 929			$ 5				152,856,874			$ (5,521,246)	(90,063,541)	26,420
Balance (in shares) at Dec. 31, 2023		9,280,159			42,236
Balance (in shares) at Dec. 31, 2023												(54,665)
Balance at Dec. 31, 2024	$ 25,969,576	$ 935				$ 5			155,794,142			$ (5,521,246)	(124,168,850)	(135,410)
Balance (in shares) at Dec. 31, 2024		9,343,533				42,019
Balance (in shares) at Dec. 31, 2024	54,665											(54,665)
Balance at Mar. 31, 2024	$ 52,821,685	$ 929			$ 5				153,494,731			$ (5,521,246)	(95,089,286)	(63,448)
Balance (in shares) at Mar. 31, 2024		9,283,939			42,236
Balance (in shares) at Mar. 31, 2024												(54,665)
Stock-based compensation	601,433								601,433
Net income (loss)	(7,335,455)												(7,335,455)
Foreign currency translation	19,632													19,632
Unrealized gain (loss), change in fair value of available-for-sale securities	12,463													12,463
Balance at Jun. 30, 2024	46,119,758	$ 929			$ 5				154,096,164			$ (5,521,246)	(102,424,741)	(31,353)
Balance (in shares) at Jun. 30, 2024		9,283,939			42,236
Balance (in shares) at Jun. 30, 2024												(54,665)
Stock-based compensation	1,048,783								1,048,783
Net income (loss)	(10,349,410)												(10,349,410)
Foreign currency translation	39,314													39,314
Unrealized gain (loss), change in fair value of available-for-sale securities	44,172													44,172
Balance at Sep. 30, 2024	36,902,617	$ 929			$ 5				155,144,947			$ (5,521,246)	(112,774,151)	52,133
Balance (in shares) at Sep. 30, 2024		9,283,939			42,236
Balance (in shares) at Sep. 30, 2024												(54,665)
Balance at Dec. 31, 2024	$ 25,969,576	$ 935				$ 5			155,794,142			$ (5,521,246)	(124,168,850)	(135,410)
Balance (in shares) at Dec. 31, 2024		9,343,533				42,019
Balance (in shares) at Dec. 31, 2024	54,665											(54,665)
Stock-based compensation	$ 612,951								612,951
Issuance of common stock pursuant to vesting of restricted stock units		$ 1							(1)
Issuance of common stock pursuant to vesting of restricted stock units (in shares)		2,829
Payment of taxes withheld on issuance of restricted stock units	(2,072)								(2,072)
Net income (loss)	(5,196,773)												(5,196,773)
Foreign currency translation	24,792													24,792
Unrealized gain (loss), change in fair value of available-for-sale securities	(975)													(975)
Balance at Mar. 31, 2025	21,407,499	$ 936				$ 5			156,405,020			$ (5,521,246)	(129,365,623)	(111,593)
Balance (in shares) at Mar. 31, 2025		9,346,362				42,019
Balance (in shares) at Mar. 31, 2025												(54,665)
Balance at Dec. 31, 2024	$ 25,969,576	$ 935				$ 5			155,794,142			$ (5,521,246)	(124,168,850)	(135,410)
Balance (in shares) at Dec. 31, 2024		9,343,533				42,019
Balance (in shares) at Dec. 31, 2024	54,665											(54,665)
Net income (loss)	$ 30,134,426
Balance at Sep. 30, 2025	$ 165,074,349	$ 4,756				$ 3	$ 64		264,553,973			$ (5,521,246)	(94,034,424)	71,223
Balance (in shares) at Sep. 30, 2025		47,548,659				29,091	638,558
Balance (in shares) at Sep. 30, 2025	54,665											(54,665)
Balance at Mar. 31, 2025	$ 21,407,499	$ 936				$ 5			156,405,020			$ (5,521,246)	(129,365,623)	(111,593)
Balance (in shares) at Mar. 31, 2025		9,346,362				42,019
Balance (in shares) at Mar. 31, 2025												(54,665)
Stock-based compensation	627,198								627,198
Net income (loss)	(10,114,270)												(10,114,270)
Foreign currency translation	95,460													95,460
Unrealized gain (loss), change in fair value of available-for-sale securities	328													328
Balance at Jun. 30, 2025	12,016,215	$ 936				$ 5			157,032,218			$ (5,521,246)	(139,479,893)	(15,805)
Balance (in shares) at Jun. 30, 2025		9,346,362				42,019
Balance (in shares) at Jun. 30, 2025												(54,665)
Stock-based compensation	800,764								800,764
Issuance of common stock pursuant to vesting of restricted stock units		$ 1							(1)
Issuance of common stock pursuant to vesting of restricted stock units (in shares)		6,036
Payment of taxes withheld on issuance of restricted stock units	(4,881)								(4,881)
Conversion of Preferred Stock into common shares			$ 205	$ 3,614		$ (2)	$ (36)			$ (203)	$ (3,578)
Conversion of Preferred Stock into common shares (in shares)			2,052,061	36,144,200		(12,928)	(361,442)
Issuance of Preferred Stock and warrants under private placement offering, net of issuance costs								$ 100
Issuance of Preferred Stock and warrants under private placement offering, net of issuance costs (in shares)								1,000,000
Reclassification of Redeemable Preferred Stock to Permanent Equity upon Requisite Approval	16,038,660						$ 100	$ (100)	16,038,560
Reclassification of Redeemable Preferred Stock to Permanent Equity upon Requisite Approval (in shares)							1,000,000	(1,000,000)
Reclassification of PIPE Warrants to Permanent Equity following shareholder approval	90,691,094								90,691,094
Net income (loss)	45,445,469												45,445,469
Foreign currency translation	(723)													(723)
Unrealized gain (loss), change in fair value of available-for-sale securities	87,751													87,751
Balance at Sep. 30, 2025	$ 165,074,349	$ 4,756				$ 3	$ 64		$ 264,553,973			$ (5,521,246)	$ (94,034,424)	$ 71,223
Balance (in shares) at Sep. 30, 2025		47,548,659				29,091	638,558
Balance (in shares) at Sep. 30, 2025	54,665											(54,665)

SAB Biotherapeutics, Inc. 10-Q